Form 4: Viemed COO Zehnder Exercises Stock, Manages Tax Obligations

Viemed Healthcare's COO, William Todd Zehnder, reported the vesting and exercise of restricted stock units and phantom share units, alongside tax-related share dispositions.

Summary

• William Todd Zehnder, Chief Operating Officer and Director of Viemed Healthcare, Inc., reported transactions on January 21, 2026, pursuant to a Rule 10b5-1(c) plan.
• Exercised 117,548 Restricted Stock Units (RSUs) and 8,554 Phantom Share Units, which were granted on January 21, 2025, and vested in their first annual installment.
• Acquired a total of 126,102 common shares (117,548 from RSUs and 8,554 from Phantom Share Units) through these exercises.
• Disposed of 35,075 common shares at $7.49 per share to satisfy tax obligations resulting from the RSU vesting.
• Disposed of 8,554 common shares at $7.49 per share as part of the cash settlement for the phantom share units.
• Following these transactions, Zehnder directly beneficially owns 374,835 common shares.
• Still holds 235,094 unvested Restricted Stock Units and 17,107 unvested Phantom Share Units.

Sentiment

Score: 6

Explanation: This Form 4 reports routine, pre-planned transactions related to executive equity compensation. The vesting and exercise of RSUs and phantom shares are expected events, and the disposition of shares for tax purposes is standard. It reflects the ongoing compensation structure for a key executive and does not indicate any significant positive or negative operational news.

Positives

• Vesting of equity awards indicates a planned compensation structure for key management, aligning executive interests with long-term company performance.
• The exercise of RSUs and Phantom Share Units by the COO demonstrates continued alignment of management's interests with shareholders.

Negatives

• Disposition of shares for tax obligations and cash settlement reduces the direct shareholding of the COO, though this is a common and expected practice.

Industry Context

This is a routine insider transaction report, common across all publicly traded companies as part of executive compensation plans. It does not provide specific industry context beyond the company's operations.

Comparison to Industry Standards

• The use of Restricted Stock Units (RSUs) and Phantom Share Units (PSUs) as part of executive compensation is a standard practice in many industries, including healthcare, to align executive incentives with long-term company performance.
• The disposition of shares to cover tax obligations upon vesting is also a common and expected practice for equity compensation across various sectors.

Stakeholder Impact

• Shareholders: The report provides transparency regarding executive stock ownership and compensation, which is generally positive for corporate governance. The slight reduction in direct holdings due to tax withholding is a normal part of equity compensation.

Next Steps

• Future vesting of the remaining 235,094 Restricted Stock Units in two equal annual installments.
• Future vesting of the remaining 17,107 Phantom Share Units in two equal annual installments.

Key Dates

Recommendation

This Form 4 details routine, pre-planned transactions by a key executive related to the vesting of equity compensation. Such filings are standard disclosures and typically do not contain information that would warrant a change in investment recommendation. The transactions reflect the normal course of executive compensation and do not signal any new operational or strategic developments for Viemed Healthcare, Inc.

Keywords

Viemed Healthcare, VMD, Form 4, Insider Trading, Stock Options, Restricted Stock Units, Phantom Shares, Executive Compensation, William Todd Zehnder, COO